Parallel Advisors’s Sutro Biopharma STRO Stock Holding History

Parallel Advisors’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.17K	Hold	47	–	–	﹤0.01%	3506
2025 Q4	$544	Hold	47	–	–	﹤0.01%	3391
2025 Q3	$404	Hold	47	–	–	﹤0.01%	3361
2025 Q2	$332	Hold	47	–	–	﹤0.01%	3362
2025 Q1	$303	Hold	47	–	–	﹤0.01%	3325
2024 Q4	$856	Hold	47	–	–	﹤0.01%	3140
2024 Q3	$1.61K	Hold	47	–	–	﹤0.01%	2937
2024 Q2	$1.36K	Hold	47	–	–	﹤0.01%	2893
2024 Q1	$2.63K	Hold	47	–	–	﹤0.01%	2740
2023 Q4	$2K	Sell	47 -6	-11%	-$190	﹤0.01%	2809
2023 Q3	$1.84K	Hold	53	–	–	﹤0.01%	2851
2023 Q2	$2.46K	Buy	53 +6	+13%	+$299	﹤0.01%	2695
2023 Q1	$2.15K	Hold	47	–	–	﹤0.01%	2749
2022 Q4	$3.76K	Hold	47	–	–	﹤0.01%	2450
2022 Q3	$3K	Hold	47	–	–	﹤0.01%	2531
2022 Q2	$2K	Hold	47	–	–	﹤0.01%	2641
2022 Q1	$4K	Hold	47	–	–	﹤0.01%	2407
2021 Q4	$7K	Hold	47	–	–	﹤0.01%	2276
2021 Q3	$9K	Hold	47	–	–	﹤0.01%	2137
2021 Q2	$9K	Hold	47	–	–	﹤0.01%	2065
2021 Q1	$11K	Buy	+47	New	+$11.2K	﹤0.01%	1889

Other funds holding STRO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Parallel Advisors's STRO Position: Q1 2026 in Review

Parallel Advisors held its Sutro Biopharma (STRO) position steady in Q1 2026 at 47 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #3506.

Parallel Advisors first reported a position in STRO in Q1 2021 and has held it in 21 quarters since. The position peaked at $11K in Q1 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

Parallel Advisors held 47 shares of Sutro Biopharma worth $1.17K as of Q1 2026.
Parallel Advisors left its Sutro Biopharma share count unchanged in Q1 2026.
Sutro Biopharma made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3506 holding.
Parallel Advisors first reported a position in Sutro Biopharma in Q1 2021 and has held it in 21 quarters since.
Parallel Advisors's Sutro Biopharma position peaked at $11K in Q1 2021.
78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.